Oncodex 8 mg Tablet is an anti-emetic medicine from Jayson Pharmaceuticals Ltd. that contains ondansetron. It is prescribed to help prevent nausea and vomiting in specific treatment situations. The doctor decides how it is used.
There are 74 brands of Ondansetron listed in Bangladesh. 8 of them have a lower unit price than Oncodex. The lowest listed price is Periset 16 mg Suppository at ৳ 1 per unit.
What is Oncodex 8 mg Tablet?
Oncodex 8 mg Tablet contains ondansetron, a medicine that works on serotonin receptors in the body that are involved in the vomiting reflex. It belongs to a group of medicines called anti-emetics. Doctors prescribe it to help prevent nausea and vomiting linked to cancer chemotherapy, radiotherapy, and after an operation. It does not treat the underlying cause of vomiting and is not a substitute for other care your doctor may advise. Only a qualified doctor should decide whether it is suitable for you.
Uses of Oncodex
Oncodex 8 mg Tablet is used to help prevent nausea and vomiting that can happen with emetogenic cancer chemotherapy, including repeat courses. It is also used to prevent and treat nausea and vomiting after surgery, and to prevent nausea and vomiting caused by radiotherapy. It is an anti-emetic medicine, meaning it acts against vomiting. Your doctor will decide if it fits your situation.
How to use Oncodex
Take Oncodex 8 mg Tablet exactly as your doctor tells you. The doctor decides the dose and how long the course lasts, so follow those instructions and do not change them yourself. Swallow the tablet as advised; ask your doctor or pharmacist if you are unsure whether to take it with food or water. If you miss a dose, ask your doctor or pharmacist what to do rather than guessing.
Side effects of Oncodex
Commonly reported side effects include headache, constipation and diarrhoea, and most of these are mild or moderate. Some people have reported a feeling of flushing or warmth, hiccups, and changes in liver enzyme tests. Rare reports include allergic-type reactions, breathing difficulty, fast heartbeat, chest pain, low potassium and shortness of breath. Tell your doctor if you notice any side effect that worries you or does not go away.
Safety and precautions
Do not take Oncodex 8 mg Tablet if you are allergic to ondansetron or any of its ingredients, or if you are taking apomorphine. Tell your doctor if you have had allergic reactions to similar anti-emetic medicines. It is not a medicine that speeds up stomach or bowel movement and should not replace other treatments your doctor advises. If you have had abdominal surgery, or have cancer-related nausea and vomiting, tell your doctor, as the medicine may hide other problems. Ask your doctor before use if you are pregnant, planning pregnancy or breastfeeding.
Frequently asked questions
What does the dosage form and strength mean for Oncodex 8 mg Tablet?
Oncodex comes as a tablet, which is a solid form you swallow. The strength is 8 mg, meaning each tablet contains that amount of ondansetron. Your doctor decides the dose and course that suit you; do not change them on your own.
What is Oncodex 8 mg Tablet used for and what kind of medicine is it?
It is an anti-emetic medicine used to help prevent nausea and vomiting linked to cancer chemotherapy, radiotherapy, and after surgery. It works on serotonin receptors involved in the vomiting reflex. Your doctor will decide if it is suitable for your condition.
Which medicines may interact with Oncodex 8 mg Tablet?
It should not be used with apomorphine. Medicines that affect liver enzymes may change how ondansetron is cleared from the body. Tell your doctor or pharmacist about all medicines, supplements and herbal products you take, and ask them to check for interactions before you start.
What is the price of Oncodex 8 mg Tablet?
The listed price is ৳ 8.06. Ask your pharmacist about availability and any dispensing charges. For advice on cost, talk to your doctor or pharmacist.
Ondansetron is a serotonin subtype 3 (5-HT3) receptor antagonist indicated:
Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy.
Prevention and treatment of post-operative nausea and vomiting.
Prevention of radiotherapy-induced nausea and vomiting.
Pharmacology
Ondansetron is a potent, highly selective 5HT3 receptor-antagonist. Its precise mode of action in the control of nausea and vomiting is not known. Chemotherapeutic agents and radiotherapy may cause release of 5HT in the small intestine initiating a vomiting reflex by activating vagal afferents via 5HT3 receptors. Ondansetron blocks the initiation of this reflex. Activation of vagal afferents may also cause a release of 5HT in the area postrema, located on the floor of the fourth ventricle, and this may also promote emesis through a central mechanism. Thus, the effect of ondansetron in the management of the nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy is probably due to antagonism of 5HT3 receptors on neurons located both in the peripheral and central nervous system. The mechanisms of action in post-operative nausea and vomiting are not known but there may be common pathways with cytotoxic induced nausea and vomiting.
Dosage & Administration
Chemotherapy-Induced Nausea and Vomiting- Adults, Pediatric patients (6 months to 18 years):
8 mg tablet/orodispersible tablet: Three 0.15 mg/kg doses, up to a maximum of 16 mg per dose.
4 mg orodispersible tablet: Three 0.15 mg/kg doses, up to a maximum of 16 mg per dose.
Injection: Three 0.15 mg/kg doses, up to a maximum of 16 mg per dose, infused intravenously over 15 minutes.
Radiotherapy-Induced Nausea and Vomiting- Adults:
8 mg tablet/orodispersible tablet: Initial Dose: 8 mg orally 1 to 2 hours before radiotherapy. Post Radiotherapy: 8 mg orally every 8 hours for up to 5 days after a course of treatment.
4 mg orodispersible tablet: Three 0.15 mg/kg doses, up to a maximum of 16 mg per dose.
Injection: Three 0.15 mg/kg doses, up to a maximum of 16 mg per dose, infused intravenously over 15 minutes.
Postoperative Nausea and Vomiting- Adults:
8 mg tablet/orodispersible tablet: 16 mg given as two 8 mg tablets
Chemotherapy-induced Nausea and Vomiting- Adults/Geriatric/Child of 12 years or over:
Highly emetogenic cancer chemotherapy: 30 ml (24 mg) Ondansetron Oral Solution administered 30 minutes before start of emetogenic chemotherapy.
Moderate emetogenic cancer chemotherapy: 10 ml (8 mg) Ondansetron Oral Solution administered 30 minutes before start of emetogenic chemotherapy. A further 10 ml dose should be administered after 8 hours of the first dose. One 10 ml dose should be administered twice a day (every 12 hours) for 1-2 days after completion of chemotherapy.
Pediatric (4-11 years): 5 ml (4 mg) Ondansetron Oral Solution should be taken 30 minutes before the start of chemotherapy. The other 2 doses should be taken 4 and 8 hours after the first dose. Then 5 ml oral solution should be administered 3 times a day (every 8 hours) for 1-2 days after completion of chemotherapy.
Oral solution:
Radiotherapy induced Nausea and Vomiting (Adults/Geriatric/Child of 12 years or over):
The recommended oral dosage: 10 ml (8 mg) Ondansetron Oral Solution 3 times daily.
For total body irradiation: 10 ml (8-mg) Ondansetron Oral Solution should be administered 1 to 2 hours before each fraction of radiotherapy administered each day.
For single high-dose fraction radiotherapy to the abdomen: one 10 ml Ondansetron Oral Solution should be administered 1 to 2 hours before radiotherapy, with subsequent doses every 8 hours after the first dose for 1 to 2 days after completion of radiotherapy.
For daily fractionated radiotherapy to the abdomen: 10 ml (8-mg) Ondansetron Oral Solution should be administered 1 to 2 hours before radiotherapy, with subsequent doses every 8 hours after the first dose for each day radiotherapy is given.
Postoperative Nausea and Vomiting (Adults/Geriatric/Child of 12 years or over):
20 ml (16 mg) Ondansetron Oral Solution 1 hour before induction of anesthesia
Oral Soluble Film:
Prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy:
Adult oral dose: 24 mg given successively as three 8 mg films 30 minutes before the start of chemotherapy.
Prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy:
Adults and pediatric patients 12 years of age and older: One 8 mg film 30 minutes before chemotherapy followed by an 8 mg dose 8 hours later. Administer one 8 mg film twice a day (every 12 hours) for 1 to 2 days after completion of chemotherapy.
Pediatric patients 4 through 11 years of age: One 4 mg film three times a day. Administer the first dose 30 minutes before chemotherapy, with subsequent doses 4 and 8 hours later. Administer one 4 mg film three times a day (every 8 hours) for 1 to 2 days after completion of chemotherapy.
Prevention of nausea and vomiting associated with radiotherapy: The adult dosage is one 8 mg film three times a day.
Postoperative nausea and vomiting: The adult dose is 16 mg given successively as two 8 mg films 1 hour before anesthesia.
Interaction
Ondansetron does not itself appear to induce or inhibit the cytochrome P-450 drug-metabolizing enzyme system of the liver. Because Ondansetron is metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes, inducers or inhibitors of these enzymes may change the clearance and hence, the half-life of Ondansetron. On the basis of available data, no dosage adjustment of Ondasetron is recommended for patients on these drugs.
Contraindications
Contraindicated in patients known to have hypersensitivity to the drug or any of its components. Concomitant use of apomorphine.
Side Effects
Frequently reported adverse events were headache, constipation and diarrhea, but the majority have been mild or moderate in nature. In chemotherapy-induced nausea and vomiting, rash has occurred in approximately 1% of patients receiving Ondansetron. There also have been reports to a sensation of flushing or warmth, hiccups and liver enzyme abnormalities. Rare cases of anaphylaxis, brochospasm, tachycardia, angina (chest pain), hypokalemia, shortness of breath have also been reported, except for bronchospasm and anaphylaxis, the relationship to Ondansetron is unclear. There have been no evidence to extrapyramidal reactions, in rare case oculogyric crisis appearing alone, as well as with other dystonic reactions without definitive clinical evidence. In case of PONV, with the exception of headache, rates of these events were not significantly different in the Ondansetron and placebo groups.
Pregnancy & Lactation
Carcinogenic effects were not seen in 2-year studies in rats and mice with oral Ondansetron doses up to 10 and 30 mg/kg per day, respectively. Ondansetron was not mutagenic in standard tests for mutagenicity. Oral administration of Ondansetron up to 15 mg/kg per day did not affect fertility or general reproduction performance of male and female rats.
Reproduction studies have been performed in pregnant rats and rabbits at daily oral doses up to 15 and 30 mg/kg per day, respectively, and have revealed no evidence of impaired fertility or harm to the fetus due to Ondansetron. There are, however, no adequate and well-controlled studies in pregnant women. Ondansetron is excreted in the breast milk of rats. So caution should be exercised when Ondansetron is administered to a nursing women.
Precautions & Warnings
Hypersensitivity reactions have been reported in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists. Ondansetron is not a drug that stimulates gastric or intestinal peristalsis. It should not be used instead of nasogastric suction. The use of Ondansetron in patients following abdominal surgery or in patients with chemotherapy-induced nausea and vomiting may mask a progressive ileus and/or gastric distension.
Storage Conditions
Store at temperature not exceeding 30ºC in a dry place. Protect from light and moisture.
Alternative brands of Ondansetron
Other brands with the same generic name, cheapest first.